Citadel Advisors’s Surmodics SRDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-1,000
Closed -$30.5K 14952
2025
Q1
$30.5K Sell
1,000
-12,200
-92% -$411K ﹤0.01% 12803
2024
Q4
$523K Buy
13,200
+4,600
+53% +$179K ﹤0.01% 8454
2024
Q3
$334K Buy
8,600
+5,200
+153% +$210K ﹤0.01% 9105
2024
Q2
$143K Sell
3,400
-1,300
-28% -$44.3K ﹤0.01% 10414
2024
Q1
$138K Buy
4,700
+1,100
+31% +$35.1K ﹤0.01% 10893
2023
Q4
$131K Sell
3,600
-100
-3% -$3.28K ﹤0.01% 10595
2023
Q3
$119K Sell
3,700
-3,500
-49% -$119K ﹤0.01% 10671
2023
Q2
$225K Buy
7,200
+3,000
+71% +$68.5K ﹤0.01% 9619
2023
Q1
$95.7K Sell
4,200
-100
-2% -$2.58K ﹤0.01% 11330
2022
Q4
$147K Buy
+4,300
New +$144K ﹤0.01% 10643
2022
Q2
Sell
-4,500
Closed -$204K 14052
2022
Q1
$204K Buy
+4,500
New +$197K ﹤0.01% 11495
2021
Q4
Sell
-6,100
Closed -$339K 14712
2021
Q3
$339K Sell
6,100
-5,400
-47% -$300K ﹤0.01% 10785
2021
Q2
$624K Sell
11,500
-10,100
-47% -$554K ﹤0.01% 9524
2021
Q1
$1.21M Buy
21,600
+13,200
+157% +$658K ﹤0.01% 7628
2020
Q4
$366K Buy
+8,400
New +$331K ﹤0.01% 8727
2019
Q3
Sell
-8,900
Closed -$384K 9721
2019
Q2
$384K Buy
+8,900
New +$376K ﹤0.01% 7210
2018
Q4
Sell
-5,100
Closed -$381K 9723
2018
Q3
$381K Buy
+5,100
New +$351K ﹤0.01% 7166
2015
Q4
Sell
-7,700
Closed -$168K 9174
2015
Q3
$168K Sell
7,700
-700
-8% -$16.4K ﹤0.01% 6371
2015
Q2
$197K Buy
8,400
+5,600
+200% +$140K ﹤0.01% 6345
2015
Q1
$73K Buy
2,800
+2,700
+2,700% +$64.3K ﹤0.01% 7119
2014
Q4
$2K Sell
100
-1,300
-93% -$27.5K ﹤0.01% 8375
2014
Q3
$25K Sell
1,400
-800
-36% -$16K ﹤0.01% 7306
2014
Q2
$47K Sell
2,200
-1,000
-31% -$21.4K ﹤0.01% 6785
2014
Q1
$72K Sell
3,200
-1,100
-26% -$26.9K ﹤0.01% 6474
2013
Q4
$105K Sell
4,300
-1,400
-25% -$33K ﹤0.01% 5567
2013
Q3
$136K Buy
5,700
+2,900
+104% +$62.2K ﹤0.01% 5111
2013
Q2
$56K Buy
+2,800
New +$70.1K ﹤0.01% 5605

Other funds holding SRDX

Citadel Advisors's SRDX Position: Q4 2025 in Review

Citadel Advisors sold out of Surmodics (SRDX) in Q4 2025, closing a stake of 365,110 shares — an estimated $10.9M sold.

Citadel Advisors first reported a position in SRDX in Q2 2013 and held it in 42 quarters. The position peaked at $10.9M in Q3 2025. 1 fund tracked by Wall St. Rank holds SRDX as of Q4 2025.

  • Citadel Advisors reported no remaining Surmodics position as of Q4 2025 after selling out during the quarter.
  • Citadel Advisors sold 365,110 Surmodics shares in Q4 2025, an estimated $10.9M.
  • Citadel Advisors first reported a position in Surmodics in Q2 2013 and held it in 42 quarters.
  • Citadel Advisors's Surmodics position peaked at $10.9M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Surmodics as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.